Gregory Pelton is a Psychiatry physician affiliated with Columbia University Irving Medical Center. OpenAlex indexes 119 publications with 8,642 citations (h-index 42); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
617 W End Ave
Suite 1b
New York, NY 100241607
Telephone
212-579-0339Registry record last updated 8 Jul 2007.
Clinical trials
- Memantine Plus Es-citalopram in Elderly Depressed Patients With Cognitive Impairment
Sponsor: New York State Psychiatric Institute
- Olfactory Deficits in MCI as Predictor of Improved Cognition on Donepezil
Sponsor: New York State Psychiatric Institute
- Combination Treatment Study for Memory Impairment and Depression
Sponsor: New York State Psychiatric Institute
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
10 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Lundbeck LLCProgram year20256 payments
- Takeda Pharmaceuticals U.S.A., Inc.Program year20253 payments
- Lundbeck LLCProgram year20246 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
97.1%SNRI26.7%Duloxetine Hcl50%Desvenlafaxine Succinate Er39%Venlafaxine Hcl Er11%Part D<11 patientsAtypical Antipsychotic12%Aripiprazole32%Quetiapine Fumarate26%Vraylar15%Olanzapine10%Rexulti10%Lurasidone Hcl9%Part D<11 patients+ 14 more classes in this area
Cardiovascular
1.7%Beta blocker1.7%Propranolol Hcl100%Part D<11 patientsMetabolism & gastrointestinal
1.2%Biguanide (metformin)1.2%Metformin Hcl100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2001–2005 per NIH RePORTER. The latest:
- Treating Mildly Cognitive- Impaired Depressed Elderly
Columbia University Health Sciences
FY2005$176,749K23MH061638 - Treating Mildly Cognitive- Impaired Depressed Elderly
Columbia University Health Sciences
FY2004$176,749K23MH061638 - Treating Mildly Cognitive- Impaired Depressed Elderly
Columbia University Health Sciences
FY2003$174,030K23MH061638
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Low Dose Lithium Treatment of Behavioral Complications in Alzheimer's Disease: Lit-AD Randomized Clinical Trial
American Journal of Geriatric Psychiatry
2021 - Donepezil Treatment in Patients With Depression and Cognitive Impairment on Stable Antidepressant Treatment: A Randomized Controlled Trial
American Journal of Geriatric Psychiatry
2018 - Lithium Treatment for Agitation in Alzheimer's disease (Lit-AD): Clinical rationale and study design
Contemporary Clinical Trials
2018 - Odor Identification Ability Predicts PET Amyloid Status and Memory Decline in Older Adults
Journal of Alzheimer s Disease
2018
Similar KOLs
Other experts from the same institution or the same specialty.
Stanley Fahn, MD
Columbia University Irving Medical Center
Rebecca Hahn, MD
Columbia University Irving Medical Center
Susheel Kodali, MD
Columbia University Irving Medical Center
Ronald Wapner, MD
Columbia University Irving Medical Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”